FDA clears application for CRISPR RNA-editing therapy developed using AI
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD) dubbed HG202, developed…
Continue Reading